quitting semaglutide cold turkey In the original clinical trials looking at (the GLP-1 in Novo Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the weight after Idiom of the Week: Cold
Description
In the EMPA-KIDNEY trial, empagliflozin improved cardiovascular and kidney outcomes in those with low GFR (regardless of level of albuminuria)
Results vary, and they may not match what patients see with injectable medications
These are miraculous drugs
Multiple studies show that when GLP-1 treatment is paired with consistent habits, especially movement, protein intake, and coaching, results last longer
